EDMONTON—Gilead Alberta ULC, a wholly-owned subsidiary of biopharmaceutical company Gilead Sciences, Inc., is investing $100M to expand and upgrade a pharmaceutical manufacturing facility and finish building a second laboratory set for completion in the spring of 2016.
The annoncement came as the company officially opened the first of two new laboratory buildings at its Edmonton campus.
“We are pleased to continue our growth here in Alberta, as evidenced by the significant investment and expansion announced today,” said Norbert Bischofberger, chief scientific officer and executive vice-president of research and development. “Our facility in Edmonton is home to many leading scientists and researchers who are working to improve patient care around the world.”
Gilead Alberta’s two new laboratory buildings, including the one that opens today, will house 170 additional highly-trained scientists in Edmonton. They will support the development and manufacturing of investigational drugs; supply active pharmaceutical ingredients (API) for clinical research programs; and contribute to new product launch supplies in the areas of hepatitis C virus (HCV), HIV/AIDS and oncology. A
The additional $100 million investment at the campus will include the construction of a new process tower for the additional manufacturing of API, a maintenance facility, and upgrades to the existing site. The process tower will expand the capabilities of the operations in Edmonton to allow for the handling of more potent compounds.